Investors Rush To This Stock on Earnings News

Rising medtech stock just got validated in a breakthrough study! Rising medtech stock just got validated in a breakthrough study!                                                                                                      You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please [unsubscribe]( here. This message is from Huge Alerts. --------------------------------------------------------------- [BSEM, a rising MedTech firm, just received another price increase from Zack’s Small Cap Research to $23.25!]( A study published in a peer-reviewed journal finds BioStem’s products offer overall better treatment efficiency and greater efficiency in general wound closure! Regenerative medicine is one of the most exciting arenas in medicine. BioStem Technologies [(BSEM)]( is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company recently had exciting news revealing that an article has validated its proprietary processing method and its placental allograft products have been published in the international, peer-reviewed journal, Health Science Reports. A study’s primary objective was to evaluate and compare the effectiveness of two wound care products for managing diabetic foot ulcers, including BioStem’s AmnioWrap2® (RE-AC), processed using the BioREtain® method, and (L-AC) processed through a more ablative method used by a leading competitor in the industry. The study found that RE-AC products required fewer applications, suggesting greater efficiency in managing wounds, and that they offered overall better efficiency! Jason Matuszewski, BioStem’s Chief Executive Officer, said, “This complete analysis of wound care products not only provides validation of BioStem’s proprietary BioREtain method, it is a testament to the clinical utility of our allografts. Current standard of care (SOC) methods are ineffective for many patients, with up to 70% of diabetic foot ulcers (DFU) not achieving healing even after 20 weeks of treatment. Our products lead to cost savings, enhanced patient comfort, and improved compliance with treatment protocols.” [Discover more about how BSEM’s products have advantages over other wound care management products on the market today and why Zack’s Small Cap Research has a price target of $23.25!]( Regards, Huge Alerts Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of BioStem Technologies Inc. (OTC:BSEM). The compensation consists of up to $2,500 and was received/will be received from sideways Frequency. This compensation should not be considered as an endorsement of the securities of adviser BioStem Technologies Inc. (OTC:BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of BioStem Technologies Inc. (OTC:BSEM) by Huge Alerts. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 8/5/2024. Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Unsubscribe]( Today's Bonus Content: [New Gold high signals “Jaws” economy…](